Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib

American Journal of Health-System Pharmacy

Volumn 61, Issue 13, 2004, Pages 1391-1394

  Tran, Fionna ^a,b   Boggie, Daniel T ^b,c,d   Delattre, Melissa L ^c   Schaefer, Monica G ^c,e   Morreale, Anthony P ^c   Plowman, Brian K ^c  

^a Western Medical Center   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VASDHS   (United States)

^d UNIVERSITY OF THE PACIFIC   (United States)

^e Vet Aff Kansas City Hlthcare S   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; ROFECOXIB; VALDECOXIB; CYCLOOXYGENASE 2; ISOENZYME; ISOXAZOLE DERIVATIVE; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; EDEMA; FEMALE; HUMAN; HYPERTENSION; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; STOMACH PAIN; TREATMENT OUTCOME; BIOASSAY; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COST CONTROL; DRUG ANTAGONISM; DRUG USE; ECONOMICS; PAIN; PHARMACOKINETICS; PUBLIC HOSPITAL;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COST SAVINGS; CYCLOOXYGENASE 2; DRUG UTILIZATION REVIEW; ENDPOINT DETERMINATION; FEMALE; HOSPITALS, VETERANS; HUMANS; ISOENZYMES; ISOXAZOLES; LACTONES; MALE; MEMBRANE PROTEINS; OSTEOARTHRITIS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULFONES; THERAPEUTIC EQUIVALENCY;

EID: 5144224857     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.13.1391     Document Type: Article

References (14)

1. American Society of Health-System Pharmacists. Principles of a sound drug formulary system. www.ashp.org/bestpractices/formulary-mgmt/ Formulary%20Management%20 Endorsed.pdf (accessed 2003 Dec 19).
2. American Society of Hospital Pharmacists. ASHP guidelines on formulary system management. Am J Hosp Pharm. 1992; 49:648-52.
3. McMurray RW, Hardy KJ. Cox-2 inhibitors: today and tomorrow. Am J Med Sci. 2002; 323:181-9.
4. Bextra (valdecoxib) package insert. New York: Pfizer; 2002 Oct.
5. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000; 284:1247-55.
6. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343:1520-8.
7. Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000; 160:1781-7.
8. Kivitz A, Eisen G, Zhao WW et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract. 2002; 51:530-7.
9. Bensen WG, Fiechtner JJ, McMillen JI et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized control trial. Mayo Clin Proc. 1999; 74:1095-105.
10. Watson DJ, Harper SE, Zhao P et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000; 160:2998-3003.
11. Food and Drug Administration. Celebrex (celecoxib capsules) NDA 20-998/S-009. www.fda.gov/cder/foi/label/2002/20998s009lbl.pdf (accessed 2003 Mar 15).
12. Geba GP, Weaver AL, Polis AB et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002; 287:64-71.
13. Jensen MP, Turner JA, Romano JM et al. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999; 83:157-62.
14. Wynne HA, Campbell M. Pharmacoeconomics of nonsteroidal antiinflammatory drugs (NSAIDs). Pharmacoeconomics. 1993; 3(2):107-23.